---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018243"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-09-08T23:59:59+00:00"
generated_at: "2026-06-23T12:40:56.429299+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KalVista Q1 net loss $23.0M ($0.94/share); cash $142.1M, down $24.1M from April

## Summary
- No revenue; R&D spending rose to $18.2M (vs. $13.7M a year ago), driven by Phase 3 KONFIDENT and preclinical costs.
- Net loss widened to $23.0M from $16.1M; cash burn reflects higher operating expenses.
- KVD824 Phase 2 KOMPLETE trial passed 50% enrollment; top-line data expected mid-2023.
- Open-label extension (KONFIDENT-S) initiated for sebetralstat; Phase 3 KONFIDENT data expected H2 2023.

## SEC filing metadata
- accession: 0000950170-22-018243
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-09-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017022018243/0000950170-22-018243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017022018243/kalv-20220908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018243
- JSON: https://secwatch.observer/filing/0000950170-22-018243.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.